Vaibhav Bhatia (Ph.D.)

A Ph.D. in Biochemistry, from the Indian Institute of Science (2010) he also has experience in business development, licensing, and alliance management in biotech and academia.
A trained biochemist and molecular biologist, he has experience in protein folding, protein chemistry, gene transfer technologies, and DNA repair. His doctorate work mainly deciphered the role of disulfide bonds in protein folding and stability. During his postdoc in Europe, he was supported by prestigious and competitive fellowships from the Spanish as well as Europen Union research programs (i.e. MINECO, EMBO, H2020, etc.). During his academic tenure, he took projects to investigate the molecular reasons that lead to retinal degeneration and breast cancer. His lead- authored work is published in elite journals like Nature, F1000research, Molecular biology of the Cell, Ophthalmology, etc.
He is a full-time entrepreneur and founder of Lamark biotech Pvt. Ltd in India and Lentistem Biotech S. L. in Spain. Both ventures are in the health sector. During his tenure as CSO of Lentistem Biotech, he made business-plan, licensed patents, raised funds (worth 240,000 Euros in 2019) for Lentistem Biotech. Collaborative by nature, he managed several projects, developed collaboration (including with Invitrogen) for the development of Lentivirus based research products and immunotherapies. He is a key player in organizing the team and converting an academic spinoff into a promising startup.
He founded Lamark Biotech in October-2018. Under his leadership and with his innovation potential Lamark now has successfully filed patents, developed collaboration, and managed to create a world-class team of scientists, managers, market research, and regulatory experts to advance their mission. He is committed to creating strong partnerships (National and International) to develop and commercialize thermostable therapeutic proteins.